Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Ovarian Neoplasms 10Breast Neoplasms 6Triple Negative Breast Neoplasms 3Sarcoma 3Fallopian Tube Neoplasms 3Prostatic Neoplasms 2Neoplasm Metastasis 2Carcinoma, Non-Small-Cell Lung 2Breast Cancer Metastatic 2Small Cell Lung Carcinoma 1Sarcoma, Ewing 1SCLC, Extensive Stage 1Recurrence 1Platinum-sensitive Relapsed Ovarian Cancer 1Osteosarcoma 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1Kenny-Caffey syndrome, Type 1 1Her-2 Negative Breast Cancer 1Glioblastoma 1Fludzoparib" and Anti-angiogenic 1Female Breast Cancer Patients 1Esophageal Squamous Cell Carcinoma 1Endometrial Neoplasms 1Colorectal Neoplasms 1Carcinoma, Renal Cell 1Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer 1

Interventions

fluzoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Female Breast Cancer Patients × fluzoparib × Clear all
NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

Zhejiang Cancer Hospital

Phase 2 Not yet recruiting
40 enrolled
Breast

Female Breast Cancer Patients

Data powered by HemOnc (CC BY 4.0) Colophon âš¡